{
    "clinical_study": {
        "@rank": "3322", 
        "arm_group": [
            {
                "arm_group_label": "IV/IM", 
                "arm_group_type": "Active Comparator", 
                "description": "Women randomized into this treatment group will receive magnesium sulfate via an IV loading dose administered manually by study staff and an IM maintenance regimen."
            }, 
            {
                "arm_group_label": "Springfusor", 
                "arm_group_type": "Experimental", 
                "description": "Women randomized into this treatment group will receive magnesium sulfate via IV infusion (with the Springfusor\u00ae pump)."
            }
        ], 
        "brief_summary": {
            "textblock": "The trial will test the equivalence of a repeat bolus protocol of magnesium sulfate\n      administered by the Springfusor\u00ae controlled pump to the Pritchard intra-muscular regimen,\n      the standard magnesium sulfate regimen used in the MAGPIE trial and many hospitals where IV\n      infusion pumps are not available.  The goal of this pharmacokinetic study is to assess the\n      pharmacological equivalence of the serum magnesium sulfate concentrations obtained in the\n      treatment of severe preeclampsia with the MAGPIE and Springfusor repeat bolus regimens.  The\n      study will also document the clinical outcomes, efficacy and acceptability of each treatment\n      for patients and staff."
        }, 
        "brief_title": "A Trial Comparing Treatment With the Springfusor Infusion Pump to the IV/IM Magnesium Sulfate Regimen", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Preeclampsia", 
        "condition_browse": {
            "mesh_term": "Pre-Eclampsia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Exhibit systolic blood pressure > 160mm Hg OR a diastolic pressure > 110 mm Hg (at two\n        times over 30 minutes) (A single higher pressure could be accepted if the clinical team\n        felt that magnesium sulfate therapy should be initiated without waiting 30 minutes).\n\n        Exhibit proteinuria > 1+; Have not given birth, or be <24h postpartum Be assessed by\n        enrolling physician to benefit from magnesium sulfate therapy Agree to comply with study\n        procedures Be > 18 years of age Give informed consent for study participation\n\n        Exclusion Criteria:\n\n        Eclamptic or seizing at the time of enrollment Received magnesium sulfate therapy 24h\n        prior to study enrollment Known serum creatinine >1.2 mg/dL. (Subject may be enrolled\n        prior to knowledge of serum creatinine but would be withdrawn if >1.2 mg/dL in order to\n        have a proper dose adjustment."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02091401", 
            "org_study_id": "4002"
        }, 
        "intervention": [
            {
                "arm_group_label": "Springfusor", 
                "intervention_name": "Springfusor infusion pump", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "IV/IM", 
                "intervention_name": "IV/IM administration", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "IV/IM", 
                    "Springfusor"
                ], 
                "intervention_name": "Magnesium Sulfate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Magnesium Sulfate"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "magnesium sulfate", 
        "lastchanged_date": "March 18, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cuernavaca", 
                    "country": "Mexico", 
                    "state": "Morelos", 
                    "zip": "62270"
                }, 
                "name": "Hospital General de Cuernavaca \"Dr. Jos\u00e9 G. Parres.\""
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Mexico"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Open-label Study to Compare the Magnesium Serum Concentrations Obtained With a Repeat Bolus Intravenous Magnesium Sulfate Regimen Administered With the Springfusor Infusion Pump to a IV/IM Magnesium Sulfate Regimen", 
        "overall_contact": {
            "email": "hbracken@gynuity.org", 
            "last_name": "Hillary Bracken, PhD", 
            "phone": "2124481230"
        }, 
        "overall_official": {
            "affiliation": "Gynuity Health Projects", 
            "last_name": "Hillary Bracken, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Mexico: National Institute of Public Health, Health Secretariat", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Blood draw times will be structured so as to perform a robust population PK analysis.  Time zero is the end of the bolus administration.  In the Springfusor arm, samples will be collected at the following times: 00:00, 00:20; 00:40; 1:20; 2:20; 3:00; 4:40; 5:20; 6:00; 6:20; 7:00; 8:00; 9:40; 10:00; 10:40; 12:00.  In the IV/IM or Magpie arm, samples will be collected at the following times: 0:00; 00:20; 00:40;1:00; 1:40; 3:20; 4:00; 4:20; 5:00; 6:00; 8:00; 8:40; 9:20; 10:40 and 12:00.", 
            "measure": "Magnesium concentration", 
            "safety_issue": "Yes", 
            "time_frame": "00:00, 00:20; 00:40; 1:20; 2:20; 3:00; 4:40; 5:20; 6:00; 6:20; 7:00; 8:00; 9:40; 10:00; 10:40; 12:00"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02091401"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Gynuity Health Projects", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gynuity Health Projects", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}